News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Beware Gilead Sciences, Inc. (GILD), Merck & Co., Inc. (MRK)'s Hepatitis C Combo Pill Impresses In Phase 2 Trial


4/10/2014 6:05:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck & Co. (MRK)’s experimental hepatitis C pill produced clinical trial results positioning the drug as a strong competitor to a potential blockbuster therapy from Gilead Sciences Inc. (GILD)

Merck’s two-drug combination once-a-day pill stopped the virus in 98 percent of newly treated patients with few major side effects, according to a mid-stage study presented today at the European Association for the Study of the Liver in London.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Seeking Alpha
Read at Reuters
Read at DNA India

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES